Literature DB >> 17683247

Oral vaccination: where we are?

Dmytro S Silin1, Oksana V Lyubomska, Vichai Jirathitikal, Aldar S Bourinbaiar.   

Abstract

As early as 900 years ago, the Bedouins of the Negev desert were reported to kill a rabid dog, roast its liver and feed it to a dog-bitten person for three to five days according to the size and number of bites [1] . In sixteenth century China, physicians routinely prescribed pills made from the fleas collected from sick cows, which purportedly prevented smallpox. One may dismiss the wisdom of the Bedouins or Chinese but the Nobel laureate, Charles Richet, demonstrated in 1900 that feeding raw meat can cure tuberculous dogs - an approach he termed zomotherapy. Despite historical clues indicating the feasibility of oral vaccination, this particular field is notoriously infamous for the abundance of dead-end leads. Today, most commercial vaccines are delivered by injection, which has the principal limitation that recipients do not like needles. In the last few years, there has been a sharp increase in interest in needle-free vaccine delivery; new data emerges almost daily in the literature. So far, there are very few licensed oral vaccines, but many more vaccine candidates are in development. Vaccines delivered orally have the potential to take immunization to a fundamentally new level. In this review, the authors summarize the recent progress in the area of oral vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683247     DOI: 10.1517/17425247.4.4.323

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  22 in total

1.  NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.

Authors:  Lindsay J Hall; Simon Clare; Gordon Dougan
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

2.  Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

Authors:  Abby Jones; Catharine Bosio; Angela Duffy; Andrew Goodyear; Martin Schriefer; Steven Dow
Journal:  Vaccine       Date:  2010-06-19       Impact factor: 3.641

3.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

4.  Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study.

Authors:  Aldar S Bourinbaiar; Vichai Jirathitikal
Journal:  Lipids Health Dis       Date:  2010-02-02       Impact factor: 3.876

Review 5.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

Review 6.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

7.  Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant with improved oral stability and immunostimulatory response.

Authors:  Harshad Harde; Ashish Kumar Agrawal; Sanyog Jain
Journal:  Pharm Res       Date:  2014-07-17       Impact factor: 4.200

Review 8.  Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

Authors:  Michael J Hackett; Jennica L Zaro; Wei-Chiang Shen; Patrick C Guley; Moo J Cho
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

9.  Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route.

Authors:  Aurélie Girard; Elodie Roques; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

10.  Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB.

Authors:  Dmitry A Butov; Yuri N Pashkov; Anna L Stepanenko; Aleksandra I Choporova; Tanya S Butova; Dendev Batdelger; Vichai Jirathitikal; Aldar S Bourinbaiar; Svetlana I Zaitzeva
Journal:  J Immune Based Ther Vaccines       Date:  2011-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.